Related Experiment Video
Updated: May 11, 2026
04:43
Targeted Knockdown of Genes in the Choroid Plexus
Published on: June 16, 2023
Caffeine and adenosine A(2A) receptor inactivation decrease striatal neuropathology in a lentiviral-based model of
Nélio Gonçalves1, Ana T Simões, Rodrigo A Cunha
1CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
Annals of Neurology
|April 30, 2013
Summary
Caffeine and adenosine A2A receptor (A2A R) inactivation reduce neurodegeneration in Machado-Joseph disease (MJD) models. This study shows A2A Rs are potential therapeutic targets for MJD.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Machado-Joseph disease (MJD) is a neurodegenerative disorder caused by an abnormal CAG expansion in the ataxin-3 gene, leading to an expanded polyglutamine tract.
- Currently, no therapies exist to prevent or modify MJD progression.
- Adenosine A2A receptor (A2A R) blockade has shown promise in mitigating neurodegeneration in other brain diseases, including early-stage Huntington's disease.
Purpose of the Study:
- To investigate the neuroprotective effects of caffeine and A2A R blockade on MJD-associated neurodegeneration.
- To determine if caffeine and A2A R inactivation can ameliorate the pathological changes observed in a mouse model of MJD.
Main Methods:
- A lentiviral vector model of MJD was established in adult male mice, with mutant ataxin-3 introduced into one striatal hemisphere and wild-type ataxin-3 into the other.
- Caffeine was administered via drinking water, and mice were analyzed at various time points (2-12 weeks) using immunohistochemistry.
- Morphological changes, including neuronal dysfunction, neurodegeneration, synaptotoxicity, and reactive gliosis, were assessed.
Main Results:
- Mutant ataxin-3 expression led to progressive neuronal dysfunction, neurodegeneration, and increased mutant ataxin-3 inclusions in the basal ganglia.
- Early signs of synaptotoxicity and reactive gliosis were observed, preceding neuronal dysfunction and damage.
- Caffeine administration and global A2A R inactivation significantly reduced these pathological modifications.
Conclusions:
- Synaptotoxicity and gliosis are early events in MJD pathogenesis.
- Caffeine and A2A R inactivation effectively decrease MJD-associated striatal pathology.
- Adenosine A2A receptors represent promising therapeutic targets for managing Machado-Joseph disease.
Related Concept Videos
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...